



NDA 21-756

Eyetech Pharmaceuticals, Inc.
Attention: Loni da Silva
Vice President, Global Regulatory Affairs
Three Times Square
12th Floor
New York, New York 10036

Dear Ms. da Silva:

Please refer to your new drug application (NDA) dated June 17, 2004, received June 17, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Macugen (pegaptanib sodium injection) 0.3 mg.

We acknowledge receipt of your submissions dated March 17, May 12 and 27, June 7, July 14 and 28, September 10, 13, 20, 22, 23, and 30, October 4, 5, 7, 15, and 29, November 10 (three), 12, 19, 22, and 23, and December 1, 6, 8, 10 (three), 13, 14 and 16, 2004.

This new drug application provides for the use of Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed draft labeling (package insert submitted December 10, 2004, carton and container labeling submitted December 16, 2004). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

The electronic labeling rule published December 11, 2003, (68 FR 69009) requires submission of labeling content in electronic format effective June 8, 2004. For additional information, consult the following guidances for industry regarding electronic submissions: *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999) and *Providing Regulatory Submissions in Electronic Format – Content of Labeling* (February 2004). The guidances specify that labeling is to be submitted in *pdf* format. To assist in our review, we request that labeling also be submitted in MS Word format. If formatted copies of all labeling pieces (i.e., package insert, container labels, and carton labels) are submitted electronically, labeling does not need to be submitted in paper.

Mylan v. Regeneron
IPR2021-00881
U.S. Pat. 9,254,338
Exhibit 2117

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

We remind you of your postmarketing study commitments in your submission dated December 10, 2004. These commitments are listed below.

1. Provide clinical information from a 2-year (minimum) clinical study to support that there are no degenerative effects on the neurosensory retina following the intravitreal administration of Macugen.

Protocol Submission: by June, 2005
Study Start: by January, 2007
Final Report Submission: by July, 2009

2. Provide clinical information from a 1-year (minimum) clinical study to support that there are no adverse effects on the corneal endothelium following the intravitreal administration of Macugen.

Protocol Submission: by June, 2005
Study Start: by January, 2007
Final Report Submission: by July, 2008

3. Provide safety and efficacy data from a 2-year (minimum) clinical study of at least two additional doses of Macugen below 0.3 mg.

Protocol Submission: by June, 2005
Study Start: by January, 2007
Final Report Submission: by July, 2009

Submit clinical protocols to your IND for this product. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled “**Postmarketing Study Protocol**”, “**Postmarketing Study Final Report**”, or “**Postmarketing Study Correspondence**.”

We remind you of the agreement in your December 10, 2004, submission to (b)(4)
(b)(4) by March, 2006.

We acknowledge the following agreements from our December 17, 2004, teleconference:

- a) Provide data by January 14, 2005, to show that the (b) (4) is sufficiently low.
- b) Provide initial materials by December 31, 2004, to educate medical providers of the controlled aseptic conditions under which the drug product must be administered in order to reduce risk to the patient and coordinate with the Division for all subsequent educational materials.
- c) Provide continued (b) (4)

In addition, submit three copies of the introductory promotional and educational materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anti-Inflammatory, Analgesic, and Ophthalmic Drug Products, and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising,
and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, contact Michael Puglisi, Project Manager, at (301) 827-2090.

Sincerely,

{See appended electronic signature page}

Jonca C. Bull, M.D.
Director
Office of Drug Evaluation V
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Jonca Bull
12/17/04 06:57:56 PM